The effect of five doses (2.5/5/10/20/40 mg/L) of the three GQD clusters (o-GQD, m-GQD, and GQD (1:3)) on the viability of the ER+/PR+/HER2+ breast cancer cell line (BT-474), two ER+/HER2− breast cancer cell lines (MCF-7 and T-47D), and a triple-negative breast cancer (TNBC; ER–/PR–/HER2–) cell line (MDA-MB-231) was determined using an MTT assay (Figure 2). The gene discussed is PGR; the disease is triple-negative breast carcinoma.